Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ANIX 
Anixa Biosciences Inc (ANIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ANIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.71% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 113.38M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 3 | Beta 0.59 | 52 Weeks Range 2.07 - 4.20 | Updated Date 09/15/2025 |
52 Weeks Range 2.07 - 4.20 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2025-09-12 | When - | Estimate -0.085 | Actual -0.07 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.95% | Return on Equity (TTM) -62.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 79163555 | Price to Sales(TTM) 481.54 |
Enterprise Value 79163555 | Price to Sales(TTM) 481.54 | ||
Enterprise Value to Revenue 368.98 | Enterprise Value to EBITDA -8.76 | Shares Outstanding 32211100 | Shares Floating 31130185 |
Shares Outstanding 32211100 | Shares Floating 31130185 | ||
Percent Insiders 5.31 | Percent Institutions 16.51 |
Upturn AI SWOT
Anixa Biosciences Inc
Company Overview
History and Background
Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines that address critical unmet needs in oncology and infectious diseases. It was founded in 2011 (although rebranded from ITUS Corporation). The company has evolved its focus over time towards novel cancer therapies and vaccines.
Core Business Areas
- Cancer Immunotherapy: Developing cellular therapies that use a patient's own immune system to fight cancer, including CAR-T therapy focused on ovarian cancer. The CAR-T is licensed from Moffitt and the company is developing its own ovarian cancer CAR-T therapy as well, as well as a breast cancer CAR-T therapy in pre-clinical stages.
- Vaccine Development: Developing vaccines to prevent cancer. This includes a vaccine targeting Triple-Negative Breast Cancer (TNBC), currently licensed to MolMed S.p.A. and partnered with Merck KGaA to develop an ovarian cancer vaccine licensed from Cleveland Clinic.
- Infectious Diseases: Historic core business is gone. Anixa no longer has any active initiatives in this area.
Leadership and Structure
The leadership team includes Dr. Amit Kumar, President and CEO. The organizational structure is typical of a biotech company, with departments focusing on research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- CAR-T Therapy (Ovarian Cancer): Anixa is developing an ovarian cancer CAR-T therapy. It is in preclinical stages and market share is currently 0%. Competitors include Novartis (Kymriah) and Bristol Myers Squibb (Breyanzi) in the broader CAR-T market, and emerging CAR-T therapies specifically targeting ovarian cancer.
- Triple-Negative Breast Cancer Vaccine: Vaccine to prevent TNBC, licensed to MolMed S.p.A. and is in early clinical development; market share is 0%. It represents a potentially preventive measure against a particularly aggressive form of breast cancer. Competitors would include other preventative treatments for breast cancer, although few vaccines are in development for this purpose.
- Ovarian Cancer Vaccine: Licensed from Cleveland Clinic; this is an immunotherapy technology focused on preventing ovarian cancer.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense R&D, high regulatory hurdles, and significant financial risk. Cancer immunotherapy and vaccine development are rapidly growing sectors, driven by increasing cancer incidence and advancements in immunological understanding. The vaccines markets are competitive markets for big pharma.
Positioning
Anixa is positioned as a clinical-stage biotech company focusing on addressing unmet needs in cancer and infectious diseases. Its competitive advantage lies in its portfolio of novel therapies and vaccines, and partnerships with institutions like Moffitt Cancer Center, Cleveland Clinic, and MolMed S.p.A..
Total Addressable Market (TAM)
The TAM for cancer immunotherapy and vaccines is substantial, estimated in the tens of billions of dollars annually. Anixa is positioned to capture a share of this TAM through successful clinical development and commercialization of its pipeline assets. The TAM for cancer is expected to reach $300 billion in the next 5 years.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy and vaccine technologies
- Partnerships with reputable institutions
- Focus on unmet needs in cancer
- Strong IP portfolio
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Dependence on partnerships
- Limited financial resources
Opportunities
- Positive clinical trial results
- Strategic collaborations and licensing deals
- Expansion of pipeline through acquisitions or licensing
- Breakthrough Therapy Designation from FDA
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from larger pharmaceutical companies
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- NVS
- BMY
- MRK
- PFE
Competitive Landscape
Anixa faces competition from larger pharmaceutical companies with greater resources and established market presence. Its competitive advantage lies in its novel technologies and targeted approach to unmet needs.
Major Acquisitions
Precision Sustainable Agriculture (PSA)
- Year: 2016
- Acquisition Price (USD millions): 1
- Strategic Rationale: Expanded the companyu2019s technology base to include a diagnostic platform for cancer, but was later divested. This platform was unrelated to Anixa's current strategy.
Growth Trajectory and Initiatives
Historical Growth: Historically, Anixa has grown through strategic acquisitions and licensing of technologies. Its growth has been tied to advancing its clinical pipeline.
Future Projections: Future growth is dependent on positive clinical trial outcomes, regulatory approvals, and successful commercialization of its product candidates. Analyst projections vary widely given the inherent risk in biotech.
Recent Initiatives: Recent initiatives include advancing the ovarian cancer CAR-T therapy into clinical trials and expanding its vaccine development program.
Summary
Anixa Biosciences is a high-risk, high-reward clinical-stage biotech company. Its focus on novel cancer immunotherapies and vaccines offers significant potential, but its early-stage clinical programs and limited financial resources pose challenges. Positive clinical trial results and strategic partnerships are crucial for its success, while regulatory setbacks and competition from larger companies remain key risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The biotechnology industry is inherently risky, and past performance is not indicative of future results. Market share numbers are estimates and should not be considered precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anixa Biosciences Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 1987-01-01 | CEO, Chairman & Co-Chair of CBAB Dr. Amit Kumar Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.anixa.com |
Full time employees 5 | Website https://www.anixa.com | ||
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.